There is no reliable way to predict one person's life expectancy with frontotemporal dementia (FTD), a form of dementia that may first affect behavior, language, or movement. The outlook depends especially on the form of FTD, age at symptom onset, early symptoms, motor involvement, and later complications. The National Institute on Aging's 2024 guide says people typically live six to eight years with FTD, although some live longer or less. The Association for Frontotemporal Degeneration estimates average survival at seven to 13 years from symptom onset.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why do survival estimates differ?
- Which forms and early features affect the outlook?
- Which later complications create the greatest risk?
- How should families discuss prognosis?
- What planning should begin after diagnosis?
Why do survival estimates differ?
Survival figures may count from symptom onset or diagnosis. Symptom onset is the point when changes first appeared; diagnosis may come considerably later. Two estimates can therefore describe similar disease courses while appearing several years apart.
In a registry of 266 European patients, median survival was 90 months from onset but 49 months from diagnosis, according to the 2024 FRONTIERS registry study. "Median" means half of the group survived longer and half survived for less time. When reviewing an estimate, check its starting point, the FTD form studied, and whether participants had motor-neuron disease. A group average is useful for planning, but it is not a countdown for an individual.
Which forms and early features affect the outlook?
FTD with amyotrophic lateral sclerosis (FTD-ALS) generally has a shorter course. ALS is a motor-neuron disease that progressively affects movement and breathing. The National Institute on Aging says FTD-ALS typically declines over two to three years and eventually prevents independent standing, walking, eating, and breathing. The FRONTIERS registry found that FTD with motor-neuron disease carried a 4.59-fold higher death hazard than behavioral-variant FTD.
That figure describes the relative rate of death within the study; it does not predict an individual survival time. A 278-person international study of genetic FTD reported a median survival of 6.94 years from symptom onset. Survival was poorer with older symptom onset, motor or language symptoms first, and FTD-ALS, according to the GENFI investigators' Lancet Neurology study. That study included only FTD caused by C9orf72, GRN, or MAPT genetic changes. Its findings should not automatically be applied to every person with sporadic FTD, meaning FTD without one of those identified genetic causes.
Which later complications create the greatest risk?
Advanced FTD may cause swallowing difficulty. Food or liquid can then enter the airway, leading to aspiration pneumonia. The National Institute on Aging identifies this as an important end-of-life risk. Balance problems can also cause serious falls.
In FTD-ALS, worsening weakness may affect walking, eating, and breathing. These physical complications can shape survival more directly than behavioral or language changes alone. Families should report new swallowing, balance, walking, eating, or breathing problems promptly. Such changes may mean that earlier care assumptions no longer match the person's needs.
How should families discuss prognosis?
Ask the clinician to explain the estimate in terms that match the individual case. Useful questions include: It can also help to request a range instead of one number. A range better reflects uncertainty and makes it easier to prepare for both a faster decline and a longer course.
- Does the estimate begin at symptom onset or diagnosis?
- Which FTD form best fits the current symptoms?
- Are there signs of ALS or other motor impairment?
- How do age at onset and the first symptoms affect the outlook?
- Which changes would signal a need to revise the care plan?
What planning should begin after diagnosis?
There is no cure for FTD or treatment proven to slow its progression. Because decision-making capacity may decline, the National Institute on Aging advises beginning care, legal, financial, and end-of-life planning soon after diagnosis.
Planning can include identifying who will make decisions, documenting the person's preferences, reviewing finances, and considering future help with eating, walking, or personal care. Arrange these discussions while the person with FTD can still participate as fully as possible.
